calcium gluconate has been researched along with Adenocarcinoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atkins, CD | 1 |
| Alberts, SR; Chitaley, U; Dentchev, T; Grothey, A; Kugler, JW; Loprinzi, CL; Nikcevich, DA; Novotny, PJ; Silberstein, PT; Sloan, JA; Wender, DB | 1 |
| Chan, A; Chay, WY; Chiang, J; Lew, KY | 1 |
| Donovan, CT; Ferencz, TM; McGurk, ML; Saif, MW; Wrzesinski, SH | 1 |
| Hashmi, S; Saif, MW | 1 |
| Asmar, L; Boehm, KA; McCollum, D; Richards, D; Sborov, M; Wilfong, L; Zhan, F | 1 |
2 trial(s) available for calcium gluconate and Adenocarcinoma
| Article | Year |
|---|---|
Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Calcium Gluconate; Chemotherapy, Adjuvant; Chi-Square Distribution; Colonic Neoplasms; Double-Blind Method; Drug Combinations; Early Termination of Clinical Trials; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Magnesium Sulfate; Male; Middle Aged; Neuroprotective Agents; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Sensation Disorders; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2011 |
Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Gluconate; Dexamethasone; Disease-Free Survival; Docetaxel; Esophagogastric Junction; Female; Gastrointestinal Diseases; Humans; Magnesium Sulfate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Premedication; Stomach Neoplasms; Taxoids; Treatment Outcome | 2008 |
4 other study(ies) available for calcium gluconate and Adenocarcinoma
| Article | Year |
|---|---|
Estimating the value of intravenous calcium and magnesium in ameliorating oxaliplatin-induced neuropathy.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calcium; Calcium Gluconate; Colonic Neoplasms; Female; Humans; Magnesium; Magnesium Sulfate; Male; Neuroprotective Agents; Neurotoxicity Syndromes; Organoplatinum Compounds; Peripheral Nervous System Diseases; Sensation Disorders | 2014 |
Preventing oxaliplatin-induced sensory neurotoxicity: a methodology perspective.
Topics: Adenocarcinoma; Antineoplastic Agents; Calcium Gluconate; Clinical Trials as Topic; Colonic Neoplasms; Early Termination of Clinical Trials; Humans; Infusions, Intravenous; Magnesium Sulfate; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Research Design; Sensory Receptor Cells | 2011 |
Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Gluconate; Drug Hypersensitivity; Female; Fluorouracil; Humans; Leucovorin; Magnesium Sulfate; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Sigmoid Neoplasms; Treatment Outcome | 2007 |
Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Anticonvulsants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Calcium Gluconate; Deoxycytidine; Diphenhydramine; Female; gamma-Aminobutyric Acid; Gemcitabine; Histamine H1 Antagonists; Humans; Magnesium Sulfate; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pregabalin; Psychomotor Agitation | 2008 |